Evommune (NYSE:EVMN) Rating Increased to Hold at Wall Street Zen

Evommune (NYSE:EVMN) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

EVMN has been the subject of a number of other reports. William Blair initiated coverage on shares of Evommune in a report on Monday, December 1st. They set an “outperform” rating for the company. Leerink Partnrs raised shares of Evommune to a “strong-buy” rating in a research report on Monday, December 1st. Cantor Fitzgerald began coverage on Evommune in a research report on Monday, December 1st. They set an “overweight” rating on the stock. Morgan Stanley started coverage on Evommune in a report on Monday, December 1st. They issued an “overweight” rating and a $36.00 price target for the company. Finally, Evercore ISI assumed coverage on Evommune in a research note on Monday, December 1st. They set an “outperform” rating and a $40.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Evommune presently has an average rating of “Buy” and an average target price of $39.33.

Evommune Stock Performance

Shares of NYSE:EVMN opened at $18.00 on Friday. Evommune has a one year low of $16.70 and a one year high of $24.03.

Evommune (NYSE:EVMN) last released its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.58) by ($1.49). The business had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $10.00 million.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.